Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Executive Summary
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.
You may also be interested in...
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures
Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.